Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Study ID
- NCT00370370
- Phase
- PHASE3
- Status
- Unknown
Conditions
- Neovascular Age-Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab — DRUGInjection of intravitreal bevacizumab
- bevacizumab + triamcinolone acetonide — DRUGInjection of bevacizumab + triamcinolone acetonide
Study Details
To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.
Key Dates
- First listed
- Aug 31, 2006
- Start date
- Nov 30, 2005
- Status verified
- Jun 2008
Study Design
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: 1Injection of intravitreal bevacizumab
- Active Comparator: 2Injection of bevacizumab + triamcinolone acetonide
Primary Outcome Measure
visual acuity
Related Studies
- Extension Study for the Port Delivery System With Ranibizumab (Portal)PHASE3 · Recruiting · Hoffmann-La Roche · Phoenix, Arizona
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)PHASE4 · Recruiting · Genentech, Inc. · Mesa, Arizona
- Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)PHASE1/PHASE2 · Recruiting · Skyline Therapeutics (US) Inc. · St. Petersburg, Florida